Cidara Therapeutics, Inc. (CDTX) Financial Statements (2024 and earlier)

Company Profile

Business Address 6310 NANCY RIDGE DRIVE
SAN DIEGO, CA 92121
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments50,43047,97632,73153,07824,63736,488
Cash and cash equivalents50,43047,97632,73153,07824,63736,488
Restricted cash and investments     3701,482
Receivables5,48325,8265,8335,0424,8338,783
Inventory, net of allowances, customer advances and progress billings1,954     
Inventory1,954     
Other undisclosed current assets4,3735,6866,5305,7796,7065,254
Total current assets:62,24079,48845,09463,89936,54652,007
Noncurrent Assets
Operating lease, right-of-use asset4,3889171,2051,4911,7642,030
Property, plant and equipment297270222173201239
Other noncurrent assets1,0611,0611,0721,2951,0131,019
Total noncurrent assets:5,7462,2482,4992,9592,9783,288
TOTAL ASSETS:67,98681,73647,59366,85839,52455,295
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities11,92113,0589,11916,52315,12215,174
Employee-related liabilities4,1173,4643,079
Accounts payable1,8993,9801,4474,2443,0912,861
Accrued liabilities10,0229,0787,6728,1628,5679,234
Deferred revenue 14,975     
Debt     3701,481
Other undisclosed current liabilities4,52422,60520,85316,52615,96315,450
Total current liabilities:31,42035,66329,97233,04931,45532,105
Noncurrent Liabilities
Long-term debt and lease obligation:    3446791,004
Liabilities, other than long-term debt3,601     
Operating lease, liability3,601  3446791,004
Other undisclosed noncurrent liabilities17,55119,23620,52524,05414,67216,225
Total noncurrent liabilities:21,15219,23620,52524,74216,03018,233
Total liabilities:52,57254,89950,49757,79147,48550,338
Equity
Equity, attributable to parent15,41426,837(2,904)9,067(7,961)4,957
Common stock997777
Additional paid in capital431,519430,585404,055402,649400,599400,398
Accumulated deficit(416,114)(403,757)(406,966)(393,589)(408,567)(395,448)
Total equity:15,41426,837(2,904)9,067(7,961)4,957
TOTAL LIABILITIES AND EQUITY:67,98681,73647,59366,85839,52455,295

Income Statement (P&L) ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Revenues      
Gross profit:      
Operating expenses(20,445)(23,013)(23,486)(25,821)(19,329)(25,370)
Other undisclosed operating income 7,61425,99010,21940,7446,2167,109
Operating income (loss):(12,831)2,977(13,267)14,923(13,113)(18,261)
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
62323216255(6)(20)
Other undisclosed loss from continuing operations before equity method investments, income taxes   (2)   
Income (loss) from continuing operations before equity method investments, income taxes:(12,208)3,209(13,107)14,978(13,119)(18,281)
Other undisclosed income from continuing operations before income taxes   2   
Income (loss) from continuing operations before income taxes:(12,208)3,209(13,105)14,978(13,119)(18,281)
Income tax expense(149)     
Other undisclosed loss from continuing operations   (272)   
Income (loss) from continuing operations:(12,357)3,209(13,377)14,978(13,119)(18,281)
Income (loss) before gain (loss) on sale of properties:14,978(13,119)(18,281)
Net income (loss) attributable to parent:(12,357)3,209(13,377)14,978(13,119)(18,281)
Other undisclosed net loss available to common stockholders, basic  (677) (3,081)  
Net income (loss) available to common stockholders, basic:(12,357)2,532(13,377)11,897(13,119)(18,281)
Other undisclosed net income available to common stockholders, diluted  677 3,081  
Net income (loss) available to common stockholders, diluted:(12,357)3,209(13,377)14,978(13,119)(18,281)

Comprehensive Income ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Net income (loss):(12,357)3,209(13,377)14,978(13,119)(18,281)
Comprehensive income (loss), net of tax, attributable to parent:(12,357)3,209(13,377)14,978(13,119)(18,281)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: